RepAs of September 30, 2025, MoonLake held cash, cash equivalents and short-term marketable debt securities of $380.5 million. The Company expects its cash, cash equivalents and short-term marketable securities, together with committed capital under a previously announced debt facility with Hercules Capital, to be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2027
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics upgraded to Buy from Neutral at H.C. Wainwright
- Buy/Sell: Wall Street’s top 10 stock calls this week
- MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi
- Moonlake Immunotherapeutics Advances Psoriatic Arthritis Treatment with Sonelokimab Study
- MoonLake Immunotherapeutics Advances with Promising Sonelokimab Study in Adolescents